Summary
AmerisourceBergen Corporation (now Cencora, Inc.) reported a modest increase in total revenue for the quarter ended December 31, 2008, reaching $17.3 billion, largely in line with the prior year. While overall revenue growth was flat, the company saw a positive shift in its customer mix towards institutional clients. The company's gross profit and operating income also saw slight increases, driven by improved gross profit margins, strong generic programs, and fee-for-service agreements, partially offset by a significant loss on its influenza vaccine program. Despite challenges such as the loss of a major retail drug chain customer and ongoing industry pressures, AmerisourceBergen demonstrated resilience. The company maintained a solid liquidity position with substantial availability under its revolving credit facilities and receivables securitization program. Management remains focused on cost efficiencies and strategic initiatives, anticipating continued revenue growth in fiscal 2009 within a projected range, supported by industry trends and internal performance improvements. The company also continued its share repurchase program and increased its quarterly dividend, signaling confidence in its financial health.
Financial Highlights
29 data points| Revenue | $17.34B |
| Cost of Revenue | $16.85B |
| Gross Profit | $489.85M |
| SG&A Expenses | $272.03M |
| Operating Income | $197.88M |
| Net Income | $111.06M |
| EPS (Basic) | $0.36 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 308.59M |
| Shares Outstanding (Diluted) | 310.18M |
Key Highlights
- 1Total revenue for the quarter ended December 31, 2008, was $17.3 billion, flat compared to the prior year, but with a favorable shift towards higher-margin institutional customers.
- 2Gross profit increased by 1% to $489.8 million, and operating income rose by 3% to $197.9 million, indicating improved profitability on a percentage basis.
- 3The company successfully managed its cost structure, with operating expenses as a percentage of total revenue declining slightly.
- 4AmerisourceBergen continued its share repurchase program, buying back $88.4 million worth of stock in the quarter, and increased its quarterly dividend by 33%.
- 5The company maintained a strong liquidity position with $470.9 million in cash and cash equivalents and significant availability under its credit facilities.
- 6The divestiture of the PMSI business in October 2008 was completed, with its results classified as discontinued operations.
- 7Anemia drug sales, particularly for oncology treatment, experienced a significant decline of approximately 27% year-over-year, impacting ABSG's performance.